EUR 139.9
(-3.38%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 58.17 Million EUR | 222.01% |
2022 | -30.64 Million EUR | -66.94% |
2021 | -37.41 Million EUR | -281.91% |
2020 | 14.65 Million EUR | 153.56% |
2019 | -19.83 Million EUR | -34.12% |
2018 | -16.32 Million EUR | -25.92% |
2017 | -12.09 Million EUR | -44.9% |
2016 | -8.35 Million EUR | -37.77% |
2015 | -6.06 Million EUR | -153.34% |
2014 | -2.39 Million EUR | -218.09% |
2013 | -752 Thousand EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 10.55 Million EUR | 144.19% |
2024 Q2 | 13.88 Million EUR | 31.27% |
2023 Q1 | 5.34 Million EUR | 157.65% |
2023 Q3 | 26.37 Million EUR | 119.72% |
2023 Q2 | 12 Million EUR | 124.79% |
2023 Q4 | -5.05 Million EUR | -119.17% |
2023 FY | - EUR | 222.01% |
2022 Q3 | -5.55 Million EUR | 49.55% |
2022 Q4 | -9.26 Million EUR | -66.88% |
2022 FY | - EUR | -66.94% |
2022 Q1 | -10.29 Million EUR | 73.29% |
2022 Q2 | -11 Million EUR | -6.87% |
2021 Q1 | 3.14 Million EUR | 270.92% |
2021 Q2 | -1.89 Million EUR | -160.22% |
2021 Q3 | -5.07 Million EUR | -167.95% |
2021 FY | - EUR | -281.91% |
2021 Q4 | -38.53 Million EUR | -659.21% |
2020 Q3 | 2.89 Million EUR | -47.98% |
2020 FY | - EUR | 153.56% |
2020 Q4 | -1.84 Million EUR | -163.67% |
2020 Q2 | 5.55 Million EUR | 41.02% |
2020 Q1 | 3.94 Million EUR | 168.62% |
2019 Q2 | -3.42 Million EUR | 54.56% |
2019 FY | - EUR | -34.12% |
2019 Q1 | -7.54 Million EUR | -43.8% |
2019 Q4 | -5.74 Million EUR | -84.16% |
2019 Q3 | -3.11 Million EUR | 9.04% |
2018 Q4 | -5.24 Million EUR | -94.51% |
2018 FY | - EUR | -25.92% |
2018 Q1 | -4.94 Million EUR | 7.27% |
2018 Q2 | -2.34 Million EUR | 52.57% |
2018 Q3 | -2.69 Million EUR | -14.96% |
2017 Q1 | -3.53 Million EUR | -0.77% |
2017 Q2 | -1.38 Million EUR | 60.75% |
2017 Q4 | -5.33 Million EUR | -190.52% |
2017 Q3 | -1.83 Million EUR | -32.18% |
2017 FY | - EUR | -44.9% |
2016 Q4 | -3.51 Million EUR | -147.85% |
2016 Q3 | -1.41 Million EUR | -21.84% |
2016 Q2 | -1.16 Million EUR | 48.49% |
2016 Q1 | -2.25 Million EUR | 14.37% |
2016 FY | - EUR | -37.77% |
2015 Q1 | -1.01 Million EUR | 0.0% |
2015 FY | - EUR | -153.34% |
2015 Q2 | -1.01 Million EUR | 0.0% |
2015 Q4 | -2.63 Million EUR | -61.09% |
2015 Q3 | -1.63 Million EUR | -61.04% |
2014 FY | - EUR | -218.09% |
2013 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | -11.71 Million EUR | 596.387% |